Arthneeti
TM

Themis Medicare Ltd

Q1 FY25Pharmaceuticals & Biotechnology

Themis Medicare Ltd Q1 FY25 Results & Presentation Highlights: Revenue, Margins & Order Book

Q1 FY25 investor presentation: what the company reported on revenue, margins and projects.

Price₹118
Market cap₹1.1K Cr
Updated24 Sept 2026
Read4 min read

Based on Themis Medicare Ltd's Q1 FY25 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.

The short version

Q1 FY25 Net Revenue: Rs. Q1 FY25 EBITDA: Rs.

From Themis Medicare Ltd's Q1 FY25 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Q1 FY25 Net Revenue: Rs. 122.99 Cr, up 27.26% YoY from Rs. 96.65 Cr in Q1 FY24 (Page 8).
  • Formulation Segment grew ~53% YoY in Q1 FY25 (Page 8).
  • Hospital Business grew over 9% YoY; Trade and Co-marketing businesses grew over 41% and 37% YoY respectively in Q1 FY25 (Page 8).
  • EBITDA for Q1 FY25: Rs. 29.18 Cr, up 34.19% YoY; PAT: Rs. 24.68 Cr, up 35.69% YoY (Page 8).
  • Management outlook: Company expects sustained growth in Trade and Hospital businesses, focusing on capacity building and new product launches, especially in Critical and Intensive Care divisions (Page 6).

2 more points management made on revenue & sales performance

Profitability & Margins

See what Themis Medicare Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

The presentation does not explicitly detail specific capex amounts, capacity expansions, new plants, or projects with associated timelines or statuses. However, it includes: - Continued investment in R&D with amounts in Rs. Cr.: ranging from Rs. 3.43 Cr in FY19-20 to Rs. 14.25 Cr in FY22-23, reflecting ongoing product development. - Expansion plans targeting new markets: Phase I (0-3 years) focuses on CIS, Latin America, GCC; Phase II (3-5 years) targets regulated markets such as EU and USA (Page 17). - Strengthening hospital business through vertically integrated manufacturing capacities: Haridwar (Formulations), Hyderabad and Vapi (Synthetic APIs) with stated capacities but no planned expansions mentioned (Page 13).

2 more points management made on capital expenditure plans

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

5x potential
1KRM Ayurveda Ltd
Rev 1Mar 1
2Accretion Pharmaceuticals Ltd
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Themis Medicare Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The provided investor presentation does not explicitly report any details regarding order book, order inflow, or pending orders. There is no mention or data related to: - Order book size or value - Order inflow trends or numbers - Pending or backlogged orders The presentation focuses on financial highlights, business segments, growth strategies, R&D capabilities, market expansion plans, and management comments, but it does not provide any direct information on order metrics.

Themis Medicare Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹77 Cr, net profit ₹9 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Themis Medicare Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Jubilant Pharmova Ltd (Q1 FY25)

    1,746 Cr, a 9% increase YoY. Key investor presentation takeaways from Jubilant Pharmova Ltd's Q1 FY25 investor presentation — and how it ranks against sector pe

  • NGL Fine Chem Ltd (Q1 FY25)

    Q1 FY25 revenue from operations: ₹90.75 crores, up 27.75% year-on-year (YoY) from ₹71.04 crores in Q1 FY24 (Page 8). Key investor presentation takeaways from NG

  • Shree Ganesh Remedies Ltd (Q1 FY25)

    Q1FY25 Revenue from Operations: ₹24.78 crore, down 8% YoY from Q1FY24's ₹26.84 crore. Key investor presentation takeaways from Shree Ganesh Remedies Ltd's Q1 FY

  • Fermenta Biotech Ltd (Q1 FY25)

    The Annual Standalone Financial Performance (Page 26) reports full-year FY24 operational revenue of INR 3,071 million, down 6.6% YoY from INR 3,289 million in…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Themis Medicare Ltd Q1 FY25 results?

Q1 FY25 Net Revenue: Rs. Q1 FY25 EBITDA: Rs.

What is Themis Medicare Ltd share price analysis?

Themis Medicare Ltd currently shows a neutral. The stock trades at a P/E of N/A with a market cap of ₹1,142 Cr. Investors should review the full earnings analysis for detailed insights.

Is Themis Medicare Ltd planning capital expenditure?

The presentation does not explicitly detail specific capex amounts, capacity expansions, new plants, or projects with associated timelines or statuses.

Keep Themis Medicare Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.